List of Excipients in Branded Drug VERQUVO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	VERQUVO	vericiguat	0006-5028	CELLULOSE, MICROCRYSTALLINE	2031-05-19
Merck Sharp & Dohme LLC	VERQUVO	vericiguat	0006-5028	CROSCARMELLOSE SODIUM	2031-05-19
Merck Sharp & Dohme LLC	VERQUVO	vericiguat	0006-5028	HYPROMELLOSE 2910	2031-05-19

Verquvo Excipient Strategy and Commercial Opportunities

Last updated: October 24, 2026

Verquvo (vericiguat) is an immediate-release, film-coated tablet approved by the FDA for adults with symptomatic chronic heart failure and reduced ejection fraction after a recent worsening event. Its commercial formulation uses conventional tablet excipients, creating opportunities in generic development, alternate sourcing, co-processed excipients, manufacturing services, and supply-chain risk management. The main technical challenges are low-dose content uniformity, reproducible dissolution under fed conditions, lubricant control, and maintaining tablet robustness across three strengths. [1]

What excipients are used in Verquvo tablets?

The U.S. prescribing information identifies six core tablet excipients:

Excipient	Primary formulation function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	High-volume commodity with supplier and quality-grade considerations
Microcrystalline cellulose	Diluent, dry binder, compactibility aid	Important for low-dose blend uniformity and tablet strength
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and supports immediate release
Hypromellose	Binder and film-coating polymer	Requires viscosity and substitution-grade control
Magnesium stearate	Lubricant	Over-lubrication can reduce hardness and slow dissolution
Sodium lauryl sulfate	Wetting agent and surfactant	May support drug wetting and dissolution consistency

The film coating contains hypromellose, talc, titanium dioxide, and iron oxide colorants. Colorant selection differs by tablet strength to distinguish the 2.5 mg, 5 mg, and 10 mg products. [1]

Verquvo does not use a complex modified-release platform, lipid vehicle, injectable excipient system, or biologic stabilizer. Its excipient strategy is therefore centered on conventional oral solid-dose manufacturing rather than delivery-system differentiation.

What is the commercial formulation profile of Verquvo?

Verquvo is supplied in 2.5 mg, 5 mg, and 10 mg tablets. The approved titration schedule begins at 2.5 mg once daily, increases to 5 mg after approximately two weeks, and may increase to 10 mg after another two weeks if tolerated. The label instructs patients to take the tablet with food. [1]

The 2.5 mg strength creates the greatest formulation risk because the active pharmaceutical ingredient represents a small fraction of total tablet mass. The formulation must distribute vericiguat uniformly through a blend dominated by excipients. Small changes in particle-size distribution, bulk density, electrostatic behavior, or blending time can affect dosage-unit uniformity.

The 5 mg and 10 mg strengths offer greater manufacturing latitude, but they still require consistent disintegration and dissolution. A generic manufacturer cannot assume that matching the nominal excipient list will produce equivalent performance. Excipient grade, particle morphology, moisture content, mixing sequence, compaction force, and lubrication time can materially change the finished product.

Which excipients create the strongest development opportunities?

Microcrystalline cellulose and lactose

Microcrystalline cellulose and lactose are the main diluent system. This combination offers multiple development paths:

• Direct sourcing from alternate qualified manufacturers.
• Substitution with different particle-size grades.
• Use of spray-dried lactose to improve flow and compactibility.
• Use of silicified microcrystalline cellulose to improve tablet strength and reduce manufacturing sensitivity.
• Optimization of the lactose-to-cellulose ratio for the 2.5 mg strength.

Co-processed cellulose-based excipients may be commercially attractive if they reduce blend segregation, improve tablet hardness, or allow lower compression force. The regulatory case is strongest when the alternative excipient system produces comparable dissolution, content uniformity, friability, and stability without changing the product’s release profile.

Croscarmellose sodium

Croscarmellose sodium is a critical performance excipient because the product is an immediate-release tablet. Its level, distribution, and addition point can affect disintegration. An intra-granular and extra-granular split may produce a different performance profile from a single external addition.

This creates an opportunity for excipient suppliers to offer application-specific grades with controlled swelling, particle size, and moisture. The opportunity is more valuable if supported by comparative dissolution data across pH conditions and after accelerated stability storage.

Sodium lauryl sulfate

Sodium lauryl sulfate is the most formulation-sensitive excipient in the product. It can improve wetting of a poorly wettable active ingredient, but excessive concentration may alter tablet disintegration, dissolution, or gastrointestinal tolerability.

Potential commercial offerings include:

• Low-variability pharmaceutical-grade sodium lauryl sulfate.
• Preblended surfactant systems.
• Alternative wetting agents with established oral safety.
• Process controls that prevent surfactant segregation during low-dose blending.

Any replacement would require a formal comparability program. A surfactant substitution is more consequential than a simple diluent substitution because it may change the dissolution mechanism and food-related performance.

Magnesium stearate

Magnesium stearate is a low-cost but high-impact excipient. Its fatty-acid composition, specific surface area, moisture content, and lubrication time can influence tablet ejection, hardness, friability, and dissolution.

For Verquvo, over-lubrication is a material risk because the product depends on rapid release. Commercial opportunities include:

• Controlled-specific-surface-area grades.
• Low-moisture or low-variability grades.
• Process analytics for lubrication endpoint control.
• Alternative lubricants where dissolution performance is preserved.

The most defensible value proposition is not simply a cheaper magnesium stearate. It is reduced batch-to-batch variability, lower compression-force requirements, or improved dissolution robustness.

How should a generic manufacturer approach Verquvo excipient selection?

A generic development program should treat the reference product’s excipient list as a starting point rather than a complete formulation blueprint. FDA ANDA standards permit differences in inactive ingredients when the proposed product remains pharmaceutically equivalent, bioequivalent, and acceptable from a safety and quality perspective. [2]

A practical development sequence is:

1. Establish the reference product’s tablet dimensions, weight, hardness, disintegration, dissolution, and assay profile.
2. Reproduce the labeled excipient classes using qualified pharmaceutical grades.
3. Prioritize the 2.5 mg strength for blend-uniformity and segregation studies.
4. Screen lubricant concentration and lubrication time.
5. Evaluate dissolution in multiple media, including fed-state-relevant conditions.
6. Confirm stability under accelerated and long-term conditions.
7. Demonstrate that any alternate excipient does not create a new safety or labeling issue.
8. Scale the formulation across 2.5 mg, 5 mg, and 10 mg strengths using a defensible proportionality strategy.

The highest-risk development variables are likely to be blend uniformity, surfactant distribution, magnesium stearate exposure, and coating weight gain. Tablet coating itself is unlikely to be the principal performance differentiator, but coating defects, moisture protection, and color consistency remain relevant to commercial quality.

What formulation patents protect Verquvo?

Verquvo’s excipient composition should not be treated as freely available merely because the inactive ingredients appear in the FDA label. The label identifies ingredients but does not disclose manufacturing parameters, particle-size specifications, granulation conditions, coating process controls, or proprietary combinations.

Relevant intellectual-property categories may include:

IP category	Potential subject matter	Generic impact
Active-ingredient patents	Vericiguat compound and related chemical claims	May control the earliest lawful launch date
Formulation patents	Tablet composition, excipient ratios, dissolution or stability attributes	May require design-around work
Method-of-use patents	Treatment of specific heart-failure populations or dosing regimens	May create carve-out issues
Manufacturing patents	Crystallization, particle-size control, blending, compression, or coating	May affect process selection
Regulatory exclusivity	New-drug or pediatric exclusivity	Can delay ANDA approval independent of formulation patents

The Orange Book remains the controlling source for current U.S. listed patents and regulatory exclusivity. Patent expiry dates should be reviewed by jurisdiction and patent family rather than inferred from the Verquvo launch date. [3]

An excipient change can reduce infringement risk only where the relevant claim requires a specific composition or process. It does not eliminate compound-patent, method-of-use, or manufacturing-patent exposure.

When does Verquvo lose exclusivity and what generic entry risks exist?

Verquvo received FDA approval in January 2021. The product is marketed by Merck and Bayer under a global collaboration covering vericiguat development and commercialization. [1, 4]

The principal generic entry scenarios are:

Entry scenario	Commercial effect	Key formulation issue
First Paragraph IV challenger	Possible six-month exclusivity for a qualifying first filer	Requires an aggressive patent and bioequivalence program
Multiple ANDA entrants after patent clearance	Rapid price erosion and contracting pressure	Lowest-cost, high-yield manufacturing becomes decisive
Authorized generic or license-backed entry	Earlier branded-generic competition	Supply reliability and channel access matter more than excipient novelty
Delayed formulation challenger	Later entry after core patent barriers	Opportunity for differentiated manufacturing economics

Verquvo is a small-molecule oral drug, so biosimilar risk does not apply. The relevant competitive threat is generic substitution through the ANDA pathway, not a 351(k) biosimilar application.

Paragraph IV activity, patent litigation, and settlement terms must be evaluated against the current Orange Book listing and federal court docket. FDA labeling alone does not establish whether a challenge has been filed, settled, or withdrawn.

What FDA regulatory issues affect alternate excipients?

FDA review focuses on the finished drug product rather than the commercial attractiveness of an excipient. The main regulatory questions are whether the alternate excipient:

• Is appropriate for the route and dosage form.
• Is used within established safety and compendial expectations.
• Changes dissolution or bioavailability.
• Creates a new impurity, elemental impurity, or microbial risk.
• Requires additional justification because of novel grade, novel function, or unusual concentration.
• Affects stability, extractables, leachables, or packaging compatibility.

ICH Q8 and Q9 principles support a risk-based approach linking material attributes and process parameters to critical quality attributes. [5, 6] For Verquvo, the most relevant critical quality attributes are assay, content uniformity, dissolution, disintegration, hardness, friability, impurities, and stability.

Which excipient suppliers and contract manufacturers have commercial opportunities?

The addressable market divides into four segments.

Qualified excipient supply

Suppliers can compete on continuity of supply for lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, and sodium lauryl sulfate. Dual sourcing is commercially valuable for a chronic cardiovascular product because a shortage can affect all three strengths.

Co-processed excipients

A co-processed diluent-disintegrant or cellulose-based compression aid could reduce manufacturing complexity. The strongest target is the 2.5 mg tablet, where blend uniformity and tablet robustness are most difficult to balance.

Contract development and manufacturing

CMOs can offer value through:

• Low-dose blending expertise.
• Roller compaction or direct-compression optimization.
• In-process content-uniformity testing.
• Multi-strength tablet manufacture.
• Film-coating scale-up.
• Commercial packaging and serialization.

The product does not require sterile filling or cold-chain distribution, which lowers manufacturing barriers compared with injectable or biologic products.

Formulation licensing

Licensing opportunities may arise for a non-infringing tablet platform that improves dissolution, reduces manufacturing variability, or enables a lower-cost excipient bill of materials. The licensing case is stronger when the platform can be reused across other low-dose cardiovascular tablets.

How strong is the excipient-based competitive position?

The excipient barrier for Verquvo is moderate, not high. The listed ingredients are widely used, and no unusual delivery technology is apparent from the approved U.S. label. The main barrier is execution:

• Achieving uniformity at 2.5 mg.
• Matching dissolution with a different excipient grade.
• Managing surfactant and lubricant effects.
• Maintaining three strengths at commercial scale.
• Separating formulation freedom-to-operate from compound and method-of-use patents.
• Securing dependable supply for all critical excipients.

A differentiated excipient strategy is more likely to reduce cost and launch risk than to create a premium product. The best commercial opportunity is a robust generic platform with alternate suppliers and validated process controls.

How does Verquvo compare with complex oral drug products?

Attribute	Verquvo	Complex oral product
Dosage form	Immediate-release film-coated tablet	May use modified release, multiparticulates, or specialized coatings
Active ingredient type	Small molecule	May have peptides, poorly soluble compounds, or sensitive actives
Manufacturing	Conventional solid-dose processing	Often requires specialized equipment or controls
Excipient complexity	Moderate	Moderate to high
Main generic risk	Content uniformity and dissolution	Release mechanism, device, or bioequivalence complexity
Biosimilar exposure	None	None for most small molecules
Supply-chain focus	Standard pharmaceutical excipients and colorants	Specialized polymers, capsules, coatings, or delivery components

Key Takeaways

• Verquvo uses a conventional immediate-release tablet platform with lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, and sodium lauryl sulfate.
• The 2.5 mg strength is the principal technical challenge because of low-dose blend uniformity.
• Sodium lauryl sulfate and magnesium stearate require tighter control than their low cost might suggest.
• Co-processed cellulose systems, alternate excipient grades, and second-source qualification are the strongest commercial opportunities.
• Generic developers must evaluate formulation, manufacturing, method-of-use, and compound patents separately.
• Verquvo has no biosimilar risk. Its competitive risk is conventional ANDA-based generic entry.
• The excipient estate is unlikely to be a major standalone barrier, but process performance can materially affect launch timing and manufacturing economics.

FAQs

Can lactose be removed from a Verquvo generic?

Yes. A lactose-free formulation may be possible, but the developer must demonstrate comparable pharmaceutical performance, stability, safety, and bioequivalence. Replacing lactose with another diluent can alter density, compaction, disintegration, and blend uniformity.

Is sodium lauryl sulfate essential to Verquvo performance?

It is not automatically essential, but its presence indicates that wetting and dissolution were important formulation considerations. Removing or replacing it requires comparative dissolution and bioequivalence support.

Which Verquvo strength is most attractive for generic formulation development?

The 2.5 mg strength is the most technically demanding and may provide the greatest value for a robust formulation platform. The 10 mg strength is generally easier to manufacture because the active represents a larger share of tablet mass.

Can a generic manufacturer use a different film-coating system?

Usually, yes, provided the coating does not alter product quality, stability, appearance requirements, dissolution, or regulatory acceptability. The manufacturer must also assess colorant differences and patient-identification risks.

Does changing the excipient composition avoid Verquvo patent infringement?

No. An excipient change may address a formulation claim, but it does not necessarily avoid compound, method-of-use, manufacturing, or other listed patent claims.

References

1. U.S. Food and Drug Administration. (2021). Verquvo (vericiguat) prescribing information. Merck Sharp & Dohme LLC and Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format of abbreviated new drug applications. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. Merck & Co., Inc. (2024). Annual report.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

6. International Council for Harmonisation. (2005). ICH Q9: Quality risk management.